You’ve more than likely heard of Ozempic, the diabetes drug hailed as a miracle weight-loss treatment. That drug is made by Danish healthcare giant Novo Nordisk. GLP-1 weight-loss and diabetes drugs have redefined what investors expect from healthcare in recent years. At eToro, we ran analysis on the firms producing these treatments, and they have delivered the kind of returns more often seen in high-growth technology stocks than in traditional pharma. Josh Gilbert, Market Analyst at eToro, said: “We built two baskets of leading drugmakers: one focused on GLP-1 producers ...